Antiangiogenic metronomic chemotherapy

Onkologie

Volumn 31, Issue 4, 2008, Pages 161-162

  Sarmiento, Roberta ^a   Gasparini, Giampietro ^a,b  

^a SAN FILIPPO NERI HOSPITAL   (Italy)

^b Division of Medical Oncology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; BEVACIZUMAB; CISPLATIN; CYTOSTATIC AGENT; CYTOTOXIC AGENT; DOCETAXEL; ETOPOSIDE; TAXANE DERIVATIVE; TROFOSFAMIDE; VASCULOTROPIN ANTIBODY; VINCA ALKALOID;

ANEMIA; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER THERAPY; CLINICAL TRIAL; DISEASE COURSE; EDITORIAL; EXPERIMENTAL STUDY; HUMAN; LEUKOPENIA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; METASTASIS; METRONOMIC CHEMOTHERAPY; NEUTROPENIA; PARENCHYMA; REMISSION; STROMA; SURVIVAL; SURVIVAL RATE; TARGET CELL; TREATMENT DURATION; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; HUMANS; LUNG NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS;

EID: 43949131075     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000119925     Document Type: Editorial

References (12)

1. Bergers G, Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-10.
2. Folkman J, Hochberg M: Self-regulation of growth in three dimensions; J Exp Med 1973:138:745-53.
3. Longo R, Sarmiento R, Fanelli M, Capaccetti B, Gattuso D, Gasparini G: Anti-angiogenic therapy: rationale, challenges and clinical studies. Angiogenesis 2002;5:237-56.
4. Gasparini G: Metronomic scheduling: the future of chemotherapy? Lancet Oncol 2001;2:733-40.
5. Gasparini G, Longo R, Toi M, Ferrara N: Angiogenic inhibitors. A new therapeutic strategy in oncology. Nature Clin Pract 2005;2:562-77.
6. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS: Continous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumour regression without overt toxicity. J Clin Invest 2000;105:R15-R24.
7. Bocci G, Francia G, Man S, Lawler J, Kerbel RS: Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Nat Acad Sci U S A 2003;100:12917-22.
8. Yap R, Veliceasa D, Emmenegger U, Kerbel RS, McKay LM, Henkin J, Volpert OV: Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy. Clin Canc Res 2005;11:6678-85.
9. Mancuso P, Colleoni M, Calleri A, Orlando L, Maisonneuve P, Pruneti G, Agliano A, Goldhirsh A, Shaker Y, Kerbel RS, Bertolini F: Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006;108:452-59.
10. Shaked Y, Bocci G, Munoz R, Man S, Ebos JM, Hicklin DJ, Bertolini F, D'Amato R, Kerbel RS: Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic durg activity and determine optimal biologic dose. Curr Cancer Drug Targets 2005;5:551-9.
11. Correale P, Cerretani D, Remondo C, Martellucci I, Marsili S, la Placa M, Sciandivasci A, Paolelli L, Pascucci A, Rossi M, Di Bisceglie M, Giorgi G, Gotti G, Francini G: A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients. Oncol Rep 2006; 16: 133-40.
12. Görn M, Habermann C, Anige M, Thöm I, Schuch G, Andritzky B, Brandl S, Burkholder I, Edler L, Hossfeld DK, Bokemeyer C, Laack E: A pilot study of docetaxel and trofosfamide as second-line «metronomic» chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC). Onkologie 2008;31: DOI: 10.1159/000118626.